Rosuvastatin and Cardiovascular Continuum. When Time Is Important

Journal of the American College of Cardiology

Volumn 55, Issue 15, 2010, Pages 1645-1646

  Barrios, Vivencio ^a   Escobar, Carlos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ROSUVASTATIN;

CLINICAL TRIAL; DISEASE SEVERITY; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

FLUOROBENZENES; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MORBIDITY; MULTICENTER STUDIES AS TOPIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONAMIDES; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 77950304018     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.031     Document Type: Letter

References (5)

1. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54 (2009) 1850-1859
2. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007) 2248-2261
3. Barrios V., and Escobar C. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther 7 (2009) 1317-1327
4. Ridker P.M., Danielson E., Fonseca F.A., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
5. Fellström B.C., Jardine A.G., Schmieder R.E., et al., AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407